System biology

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Automation / robotics #Biomarkers #Cell culture #Cellular & Molecular biology #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Microfluidics #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics

Data Overflow Progress in Automating and Streamlining Data

Data Overflow Progress in Automating and Streamlining Data By Peer Staehler The genomic world moves faster and faster. The pool of data has exploded exponentially in the past few years due to the growing knowledge about the relevance of genomic findings for medicine and the environment. Like all other developing… Read More

#Archive

#Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Transcending Proteasome Inhibition for the Treatment of Cancer

Transcending Proteasome Inhibition for the Treatment of Cancer By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathway for controlling protein degradation is the ubiquitin proteasome system (UPS). Specific pharmacological inhibition of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #System biology #Systems biology #Target validation

The Potential of Molecular Imaging for Drug Discovery & Development

The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Dispense and Imaging Assays – Moving towards a more balanced use of both fluorescence and flash luminescent readouts

Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More

#Archive

#Animal models #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Immunology #Lead discovery #Oncology #Regulatory #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advances in Antibody Therapy – A promising new approach to how we treat cancer

Advances in Antibody Therapy - A promising new approach to how we treat cancer By Dr Patrick A Baeuerle Antibodies available today for cancer treatment, while effective, are typically used in combination with standard therapies because their activity as monotherapy is limited. Currently, four conventional antibody products dominate the oncology… Read More

#Archive

MicroRNA
#Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Genetics / genomes #Genetics / genomics #In Silico Biology #PCR #RNA #Stem cells #System biology #Systems biology #Therapeutics

Trends in the microRNA Marketplace

Trends in the microRNA Marketplace By Kathy Gray and Dr Enal Razvi In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market analyses are presented in detail in a recently published MicroRNA 2008 market report. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #In Silico Biology #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Progress in Systems-Based Analysis of Cellular Signalling

Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Needs and challenges in High Throughput Screening

Needs and challenges in High Throughput Screening By William Downey, Dr Helen Nicely and Dr Lynne Sopchak High throughput screening (HTS) groups face similar challenges as the pharmaceutical and biotechnology industry as a whole faces. HTS groups are looking for ways to improve effectiveness in lead discovery, increase their productivity… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Perspectives for ADMET Integration in the Discovery Process

Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More

#Archive

#Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #RNA #Screening #System biology #Systems biology

Compound Storage Evolution: Unlocking the right combination

Compound Storage Evolution: Unlocking the right combination By Husam Fayez, Dr John Morin and Dr Jeff Paslay Delivering the correct compound, at the right concentration, to the correct place, at the expected time across different facilities, should be the aim of all liquid sample management teams. This article discusses how… Read More

#Archive

#Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Systems biology #Target validation #Toxicology

Next Generation DNA Sequencing Technologies

Next Generation DNA Sequencing Technologies By Dr Bruce E. Taillon and Brendon Hill Human genetics is the foundation of disease as well as the response to pharmaceutical agents. Today, promising drugs are abandoned due to the lack of significant efficacy in broad patient populations. Recently, blockbuster drugs have been removed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #Sequencing #Stem cells #System biology #Systems biology

21st Century Vaccines – A Development Renaissance

21st Century Vaccines - A Development Renaissance By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mumps and tetanus - vaccines… Read More

#Archive

#Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Orphan drugs #PCR #Pharmacology #Regulatory #Screening #Stem cells #System biology #Systems biology

GPCRs – New Strategies for an Old Target Class

William Downey and Dr Shauna Farr-Jones GPCRs are the most studied drug target class and have a proven record as valuable drug targets, with 40-50% of marketed drugs being modulators of GPCR function. Despite the intense effort focused on these targets by the pharmaceutical industry over many years, numerous challenges… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomes #High throughput screening #Immunology #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics

The Power of APTAMERS in the Drug Discovery Process

The Power of APTAMERS in the Drug Discovery Process Professor Michael Famulok Methods of combinatorial biochemistry allow the identification of nucleic acid sequences, or aptamers, which can bind their target molecules with high affinity and specificity and are able to efficiently inhibit their biological function. Macugen, the first aptamer-based drug… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Business #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High throughput screening #Lead discovery #Lead optimisation #Preclinical #RNA #Screening #System biology #Systems biology

The Deming Approach to Quality In Pharmaceutical Research

The Deming Approach to Quality In Pharmaceutical Research By John H. Van Drie We explore the relevance to pharmaceutical research of the ideas of W. Edwards Deming, the statistician whose ideas on quality transformed the manufacturing sector of post-war Japan. To enhance productivity in pharmaceutical research, we have tended to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biomarkers #Business #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #PCR #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Technology, Bane or Bonanza for the Pharmaceutical industry?

Technology, Bane or Bonanza for the Pharmaceutical industry? By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine Productivity in the pharmaceutical industry has long held well-documented concerns.   While the adoption of new technologies into the drug discovery and development process has often been seen as a… Read More

#Archive